-
Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer
•
Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276), based in China, has announced that its market approval filing for the programmed death-1 (PD-1) monoclonal antibody camrelizumab, in combination with multi-kinase inhibitor famitinib for recurrent or metastatic cervical cancer, has been accepted for review by the National Medical Products Administration (NMPA). This…
-
Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules
•
Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm Ten63 Therapeutics, aimed at identifying multiple novel molecules across various indications with significant unmet medical needs. Financial details of the partnership have not been disclosed. This collaboration will leverage BI’s extensive pre-clinical and clinical expertise…
-
Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma
•
Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it has received New Drug Application (NDA) approval from the regulatory authority in Macau for its product Xpovio (selinexor). This approval is specifically for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R…
-
Innovent Biologics Expands Partnership with Synaffix for New ADC Development
•
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a subsidiary of Lonza (SWX: LONN). This follows an initial agreement from June 2021, during which Innovent successfully utilized Synaffix’s antibody-drug conjugate (ADC) technology platforms on a non-exclusive basis to develop IBI343, an anti-CLDN18.2 ADC that…
-
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
•
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics, focusing on cell therapies aimed at preventing allograft rejection in solid organ transplants. Under the agreement, Taiwan Bio will leverage its manufacturing expertise in cell therapy to enhance TRACT’s immune-modulating regulatory T cell therapy platform.…
-
Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition
•
Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for the Prevenar 13 vaccine in China, with the vaccine now reportedly under the management of local partner Kyuan, a subsidiary of pharmaceutical logistics giant Shanghai Pharma. The US pharmaceutical giant has been engaged in global…
-
Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and Drug Administration (FDA) for its first-in-class orphan drug Fabhalta (iptacopan) as an oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). The approval was granted based on Phase III clinical data that demonstrated a significant…
-
AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience
•
AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in machine learning and wet lab platforms, to discover and develop next-generation antibodies for multiple therapeutic targets in oncology and neuroscience. BigHat will receive an upfront payment of USD 30 million, with the potential for up…
